Rigel Pharmaceuticals | RIGL - Debt


Rigel Pharmaceuticals reported $59.69M in Debt for its fiscal quarter ending in June of 2024.





Debt Change Date
Agenus USD 35.54M 2.34M Mar/2025
Amgen USD 57.32B 2.72B Mar/2026
Anika Therapeutics USD 0 0 Mar/2025
Arrowhead Research USD 983.69M 5.77M Jun/2026
AstraZeneca USD 32.24B 1.68B Jun/2026
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Bristol-Myers Squibb USD 46.43B 711M Mar/2026
Celldex Therapeutics USD 1.91M 428K Mar/2026
Daiichi Sankyo JPY 300.48B 99.34B Mar/2026
Eli Lilly USD 43.37B 867M Mar/2026
Halozyme Therapeutics USD 2.14B 2.01M Mar/2026
Heron Therapeutics USD 149.65M 157K Sep/2024
Intrexon USD 0 13.82M Jun/2024
Ionis Pharmaceuticals USD 1.91B 425.5M Jun/2026
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
Ligand Pharmaceuticals USD 451.98M 486K Mar/2026
MacroGenics USD 36.51M 500K Mar/2026
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
Pfizer USD 63.19B 536M Jun/2026
Regeneron Pharmaceuticals USD 2.71B 400K Jun/2026
Rigel Pharmaceuticals USD 59.69M 90K Jun/2024
Sangamo BioSciences USD 0 0 Jun/2022
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Veracyte USD 39.33M 321K Mar/2026